Mantle cell lymphoma (MCL) patients represent a difficult problem, sometimes to establish the diagnosis but mostly because of their refractoriness to standard lymphoma treatments. Which treatments to apply and to whom is not yet defined. In this study, we attempted to analyze the clinical features, to identify the major prognostic factors, and to evaluate the outcome of 121 MCL patients treated in our institution between 1979 and 1997. Clinical data, treatment modalities, and International Prognostic Index (IPI) score were evaluated. Median age was 63 years. Patients usually presented with advanced stage disease (87%), disseminated lymph nodes (57%), bone marrow involvement (79%), but with a good performance status (PS) (81%). Lymphocytosis Ͼ4000/l and/or peripheral blood involvement was present in 36% of cases, and gastrointestinal disease in 18%. The t(11;14)(q13;q32) and/or bcl-1 rearrangement was detected in 47/57 studied cases. Median overall survival (OS) was 3.12 years and a longer survival was significantly associated with younger age (Ͻ70 years), good PS (Ͻ2), localized disease (stage I-II), fewer than two extra-nodal sites, absence of spleen or peripheral blood involvement, normal serum LDH and ␤2-microglobulin levels, and hemoglobin level greater than 12 g/dl. However, the IPI failed to identify patients with longer OS and in a multiparametric analysis, only older age, hemoglobin less than 12 g/dl, poor PS, and blood involvement were associated with a poorer outcome. Treatment modalities had no impact on survival with 75% of patients relapsing or progressing. Our data showed that the poor outcome of MCL patients is mainly related to adverse patient characteristics, a highly disseminated tumor, and some unknown parameters associated with the refractoriness to standard therapy.
Introduction
In 1991, Raffeld and Jaffe proposed the term 'mantle cell lymphoma' to the entity previously known as centrocytic lymphoma, lymphocytic lymphoma of intermediate grade of differentiation, or mantle zone lymphoma. [1] [2] [3] [4] [5] [6] A common biological abnormality for this lymphoma was described with the identification of the t (11;14) translocation in the majority of cases. This chromosomal abnormality results in rearrangement of the bcl-1 gene and deregulation of cyclin D1, which is a nuclear protein that controls the progression of G1 and G1/S transition. [6] [7] [8] The normal counterpart of this lymphoma is thought to be a population of CD5 + CD10 − CD23 − mantle zone B cell. 9 Although clinical and pathological aspects have been well described, 5, 10, 11 controversy still remains about the best treatment and the most valuable prognostic factors. 12, 13 Although this is a rare lymphoma that represents no more than 10% (2.5-11%) of all lymphoma subtypes, 14, 15 it recently gained much interest because of its poor outcome which constitutes a major disappointing problem for clinicians. This lym- phoma usually begins as a disseminated disease with widespread involvement of lymph nodes, spleen, bone marrow and other extranodal sites, specially the gastrointestinal tract and Waldeyer ring. However, patients usually present a good performance status (PS) at diagnosis although adverse prognostic factors, such as high serum lactic dehydrogenase (LDH) and ␤2-microglobulin levels, may be present. Initially, these patients usually respond to different types of therapy, but relapses are frequent and rapid. With relapses, the disease becomes more disseminated and gains characteristics of aggressiveness and the response to therapy becomes worse or very short. Fatal evolution is ineluctable, with a median overall survival being the worst compared to other lymphoma categories, ranging between 3 and 4 years in all studies. 15 In this study, we attempted to evaluate the clinical features, prognostic factors and outcome of the 121 MCL patients treated in our institution.
Patients and methods

Patient population and characteristics
Among 1919 consecutive non-Hodgkin's lymphoma patients treated in our institution between 1979 and 1997, 121 cases (6.8%) have been diagnosed as MCL. All these cases were retrospectively reviewed and complete disease history from initial diagnosis, clinical features, treatment modalities, and follow up information were collected.
Evaluated parameters and initial staging procedures included physical examination, complete blood count with differential, serum chemistry panel, serum ␤2-microglobulin and LDH levels, chest radiography, CT scan of the thorax, abdomen and pelvis, and bone marrow biopsy. Extranodal sites were biopsied whenever involvement was suspected. Patients were staged according to the Ann Arbor system, and PS was evaluated according to the Eastern Cooperative Oncology Group (ECOG) scale. Patients were assigned to one of four prognostic scores according to the International Prognostic Index (IPI) that takes into account the presence or absence of prognostic factors (serum LDH level, age, stage, performance status and number of extranodal sites). 16 
Tumor characteristics
Diagnosis relied on a typical morphology and/or a typical immunophenotype. For cases diagnosed before 1992, pathology specimens have already been reviewed as part of other studies. 15, 17 Diagnosis relied on a lymph node biopsy in 82 cases, Waldeyer ring tumor biopsy in 12, bone marrow biopsy in 12, gastrointestinal tract biopsy in eight, splenectomy in four, parotid gland, prostate, or skin biopsy in one case each. These patients were divided into two groups for the pattern of infiltration, diffuse vs nodular (defined only on lymph node specimens), and for the type of lymphoma cells, small to medium cells vs large cells (defined as more than 20% large cell in the infiltration). No case with the mantle zone aspect was individualized. Immunophenotyping varied according to the date of biopsy; CD5 immunophenotyping was available in 69 patients, CD10 in 39, CD23 in 55, CD43 in 19, heavy chain immunoglobulin in 52 and light chain in 53 cases. Cytogenetic analysis was performed in 43 cases and the bcl-1 rearrangement at the MTC region was studied using the PCR amplification technique in 51 cases. PCR amplification of the bcl1-JH rearrangement was performed with standard techniques using a consensus JH primer (ACCTGAGGAGACGGT-GACCAGGGT) and an oligonucleotide for the bcl1-MTC region (GGGCTTCTCTCACCTACTAATATCG). 7 
Treatment modalities
Most patients received chemotherapy as part of their primary treatment: 68 patients received an anthracycline-containing regimen and 43 patients had chemotherapy without anthracycline (chlorambucil: 22 patients; fludarabine: 12; other multidrug regimens: eight; and anti-CD20 antibody: one patient). Six patient had no initial treatment; three received exclusive radiotherapy; and one patient underwent a splenectomy with no further treatment.
Thirteen patients treated with an anthracycline-containing regimen received further consolidation by a high-dose myeloablative radio-chemotherapy and stem cell transplant. These patients were selected for high-dose chemotherapy because of first-line treatment failure (refractoriness or relapse), or because of two or three unfavorable prognosis parameters. The source of stem cells and the conditioning regimen were quite uniform: only one patient, treated in 1989, was transplanted with bone marrow cells after receiving CBV (cyclophosphamide, BCNU, etoposide) as a conditioning regimen. All other patients received peripheral blood stem cells (PBSC) combined with bone marrow cells in one case. The conditioning regimen consisted of cyclophosphamide plus etoposide and fractionated total body irradiation in these cases. 18 Eighteen responding patients (CR or PR) received maintenance therapy: six with chlorambucil ± prednisone and 12 with interferon, seven of them after myeloablative therapy with PBSC transplant.
Assessment of response
Complete response (CR) was defined as the complete disappearance of all physical signs of disease with complete resolution of all previously abnormal investigations including bone marrow biopsy. Partial response (PR) was defined as the regression of at least 50% of all measurable disease. Failure was determined as of less than PR, or progressive disease, or death during treatment.
Statistical methods
Overall survival (OS) was calculated from the date of diagnosis until death from any cause or loss to follow-up. Freedom from progression (FFP) survival was calculated from the date of the beginning of the treatment to the date of progression or death or last contact if the patient did not progress. Diseasefree survival (DFS) was defined for patients who achieved CR from the date of the beginning of the treatment until relapse, death or last contact. Actuarial survival curves were estimated by the Kaplan-Meier method 19 and compared by the log-rank test. Chi-square test was used in univariate analysis to determine whether variables were predictive for response. P values Ͻ0.05 were considered to indicate significant statistical differences. A multivariate Cox regression analysis was done for parameters at diagnosis associated with survival. 20 Parameters entered in the analysis were age, stage, B symptoms, PS, blood involvement, large spleen, bulky tumor, number of extranodal locations, hemoglobin, LDH, ␤2-microglobulin, and serum albumin levels. In one analysis the IPI score was not included in the analysis and the second analysis was stratified on IPI scores. A logistic regression was realized to determine the parameters associated with a response to therapy.
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Results
Tumor characteristics
All cases were reviewed by at least one expert pathologist. The initial diagnosis made by the local pathologists was modified in 47.5% of cases (n = 58); 15 cases being previously classified as diffuse small cleaved cell lymphoma (subtype E according to the Working Formulation), nine cases as chronic lymphocytic leukemia (CLL), and 39 cases were included in different other histologic categories. Seventy-three percent of the cases having a wrong initial diagnosis were cases diagnosed before 1992.
In this study, the architectural pattern of the lymph node was diffuse in 54 specimens and nodular in 28. A predominance of large and/or blastoid cells was observed in 10 patients, the other cases having the classical small to mediumsized cell infiltration with 21 of them having some large cells but less than 20%. Twenty-four patients showed a transformation to a more aggressive histology with predominance of blastoid cells during the course of their disease. Median time to transformation (after diagnosis) was 26 months (range 3 to 54 months).
CD5, CD10, CD23 and CD43 immunophenotyping was available in 69, 39, 55 and 19 patients, respectively, and were found positive in 64, one, three and 12 cases, respectively. The case with a positive reaction to CD10 antigen presented a double CD10 and CD5 population. This case was reviewed by an expert pathologist and kept as a MCL because of typical morphology. Cytogenetic analysis was done in 43 cases and a typical t(11;14)(q13;q32) was found in 38 of them. The bcl-1 rearrangement at the MTC region was studied in 51 cases and was found in 25 cases. The t(11;14)(q13;q32) and/or bcl-1 rearrangement was detected in 47 of the 57 cases studied by at least one of the two techniques.
Patient characteristics
The main clinical features at diagnosis are illustrated in Table  1 . The median age was 63 years (range, 32-84 years). The male to female ratio was 2:1. One hundred patients had stage IV disease (83%), five had stage III (4%), eight had stage II (6.5%), and eight other patients had stage I disease (6.5%). Only seventeen patients had B symptoms at presentation. Fifty-seven percent of the patients presented with generalized lymph node enlargement while 13% (n = 16) had only extranodal disease. Bone marrow involvement was observed in 79% (n = 96) of the patients and peripheral blood involvement and/or absolute lymphocyte count Ͼ4000/l in 36% (n = 44) of them. Only 11 patients had a leukemic picture with absolute lymphocytosis Ͼ10 000/l. Twenty-one patients (18%) had gastrointestinal disease and 15 of them presented a colonic involvement. Other extranodal sites are illustrated in Table 1 . Bulk disease (larger than or equal to 10 cm) was present in 19% (n = 24) of cases (abdominal mass in nine cases, splenic in 10, and other in five). When the international prognostic index (IPI) was applied to the 97 patients with sufficient available data (94 patients had available data for the five parameters of the IPI and three other patients already presented with four adverse prognostic factors without considering the serum LDH level), four subgroups were identified: low risk subgroup (n = 14; 14%), lowintermediate risk subgroup (n = 27; 28%), intermediate-high risk subgroup (n = 28; 29%) and high risk subgroup (n = 28; 29%).
Fourteen patients (12%) had another cancer some time during their medical history: 10 patients presented cancer before the diagnosis of lymphoma (median 3 years; range 0.5 to 31 years) and four patients after the diagnosis of MCL (median 1.67 years; range 1 to 7 years). The primary site was the skin in three cases, colon, prostate, breast, and thyroid in two cases each, and lung, vocal cord, and kidney in one case.
Treatment and response
After the first treatment, 34 patients were in CR, 34 in PR (overall response rate 68%), 49 patients failed to respond, and one patient died of massive pulmonary embolism. Of the 68 patients treated with an anthracycline-containing regimen, 20 reached a CR, 28 a PR (overall response rate 71%), 16 failed to respond, and one patient died. Details concerning response to initial treatment are listed in Table 2 .
Univariate analysis showed that response to primary treatment was strongly associated with a low risk or low-intermediate risk IPI (P = 0.0001), Ͻ2 extranodal sites (including spleen, bone marrow and peripheral blood) (P Ͻ 0.0001), normal ␤2-microglobulin level (P = 0.0003), presence of B symptoms (P = 0.04), localized stage (P = 0.0014), absence of splenomegaly (P = 0.01), absence of peripheral blood involvement, and absolute lymphocyte count Ͻ4000/l (P = 0.008), but not with age, gender, PS, presence of anemia, serum albumin or LDH levels, nor to the histologic pattern of infiltration, the presence of large cells at diagnosis, or to the treatment modality (anthracycline vs non-anthracycline containing regimen) (Table 3 ). In a logistic regression analysis, a response to treatment, either CR or PR, was associated with no gastrointestinal location (P Ͻ 0.05), low ␤2-microglobulin level (P Ͻ 0.05), and with borderline significance absence of B symptoms and normal serum albumin level.
Twenty-two patients initially treated with chlorambucil and 12 patients treated with fludarabine were compared to the rest of the study population, to the anthracycline-treated patients, and to 43 other patients treated with non-anthracycline-containing regimens. No significant difference was found regarding the achievement of a complete response. However, patients treated with the anthracycline-containing regimen achieved significantly more frequently a CR or PR in a logistic regression analysis. The type of treatment was the most significant parameter (P Ͻ 0.001) followed by the level of ␤2-microglobulin level (P = 0.01).
Evolution and survival
Seventy-five percent of the patients showed a progression of the disease or a relapse after initial treatment; with a median FFP survival of 0.94 years (Figure 1) . A short FFP survival was 
Figure 1
Overall survival (OS), disease-free survival (DFS) and freedom from progression survival (FFP) for the 121 patients. strongly associated with the presence of B symptoms (P = 0.01), high ␤2-microglobulin level (P = 0.03), and the presence of peripheral blood involvement (P = 0.02).
Median overall survival was 3.12 years (Figure 1 ). The prognostic impact of clinical and biologic parameters at diagnosis is presented in Table 3 . Longer survival appeared to be significantly associated with younger age (Ͻ70 years) (P = Overall survival according to the presence of peripheral blood involvement (PBI).
0.0075), good PS (P = 0.001), localized disease stage (P = 0.02), no enlarged spleen, no peripheral blood involvement (Figure 2 ) or absolute lymphocyte count Ͻ4000/l (P = 0.04 and P = 0.0017, respectively), low number of extranodal sites (P = 0.00034) (Figure 3) , normal serum LDH and ␤2-microglobulin levels (P = 0.009 and P = 0.04, respectively), absence of anemia (P = 0.014), good IPI score (P = 0.00003). Overall survival according to extranodal sites number (ENS).
Median overall survival for the 14 low risk patients, the 27 low-intermediate risk, the 28 intermediate-high risk, and the 28 high risk patients was respectively 2.97, 2.36, 2.08 and 1.24 years (Figure 4) . A response to first-line treatment, either CR or PR, was associated with a longer survival (P = 0.02).
Gender, presence of B symptoms, another associated primary cancer, bulky tumor, gastrointestinal involvement, serum albumin level, presence of monoclonal component, histologic growth pattern, percentage of large cells at diagnosis, blastoid transformation, detection of the t (11;14) or the bcl-1 rearrangement, as well as the use of an anthracyclinecontaining regimen were not associated with a longer survival. Overall survival of patients receiving intensive therapy and peripheral blood stem cell transplant after first-line treatment was not significantly superior to the overall survival of the rest of the population. 18 Twenty-four patients showed a histologic transformation and median survival after transformation was 0.58 years.
A multivariate analysis was run to determine the initial parameters associated with shorter survival. In the first run, IPI was not included in the analysis and the parameters found to be significantly associated with short survival were age older than 70 (P Ͻ 0.0005), poor PS (P = 0.001), blood involvement (P = 0.001), hemoglobin level Ͻ12 g/dl (P Ͻ 0.05), and bulky
Figure 4
Overall survival according to the International Prognostic Factor (IPI tumor (P = 0.01). When the IPI was included in the analysis, the results did not change. The last analysis was stratified on IPI scores and determined that the parameters associated with a short survival were bulky tumor (P Ͻ 0.002), anemia (P Ͻ 0.01), blood involvement (P Ͻ 0.01), and older age (P Ͻ 0.02).
Although it was not a randomized study, responding patients (CR or PR) were evaluated in order to assess the impact of maintenance therapy on overall survival and FFP survival. We did not find a significant difference between patients receiving maintenance therapy and other responding patients. We did not find a significant difference either, when we compared patients receiving chlorambucil and those receiving interferon as maintenance therapy.
At the time of the analysis, 77 patients (64%) had died with a median survival of 3.12 years (range of survival for deceased patients: 0.22 to 11.34 years). The cause of death was progression of the disease in 45 cases (58%), treatment related (severe infections or hemorrhage) in 23 cases (30%), and death unrelated to the lymphoma or its treatment in nine other cases (12%); four patients were lost to follow-up (three had progressive disease and the other CR at the date of the last contact).
Discussion
Although increasing numbers of recent publications have described the characteristics, natural history, and prognostic factors of mantle cell lymphoma patients, confusion remains about the latter, and many questions are still unresolved, especially those concerning the most adequate treatment. In this analysis of 121 MCL patients, the largest retrospective series published to date, we attempted to find answers to these questions. The clinical features were comparable with those previously described:
22-31 a median age of 63 years, male predominance, good PS with few patients presenting B symptoms at diagnosis, advanced disease stage, widespread lymph node involvement with more than one extranodal site, the bone marrow being the most frequently infiltrated (79%), followed by the spleen (47%), the peripheral blood (36%), the gastrointestinal tract (18%), the liver (13%), and the Waldeyer ring (12%).
One of the most striking findings in our study was that a relatively high number of cases (30%) had a circulating monoclonal component, even if it was often at very low level. This could be explained by an immunoglobulin secretion by lymphoma cells, as in some cases proposed by Preudhomme et al. 32 Another explanation could be the one suggested by Hirokawa et al 33 that a clonal Ig production may have been driven by autoreactive T cells, presumably against the neoplastic B cells.
Several authors attempted to determine which clinical and pathological factors were of prognostic value. In particular, younger age at diagnosis, limited stage of disease, normal serum LDH level, good IPI, and achievement of a CR after initial treatment were found to be associated with a longer survival, [24] [25] [26] 28, 30, 31 but not in all retrospective series. 28, 30 In this study, we confirm that a longer survival was significantly associated with younger age (Ͻ70 years) and good PS. However, we associated these parameters with the absence of peripheral blood involvement and absence of anemia. The most significant prognostic parameter in our series was the presence of peripheral blood involvement, a parameter already identified in several other studies. 25, 28, 31, 34, 35 The IPI per se could only individualize the high risk subgroup as being worse than the other but was not able to discriminate between the three other risk groups (Figure 4 ). In fact, the so-called standard prognostic parameters such as IPI score, stage, PS, number of extranodal sites, LDH and ␤2-microglobulin levels were not the most important parameters in our study. It may suggest that MCL are different from other lymphomas. The two histologic subgroups did not differ significantly regarding the response to therapy, FFP survival, or overall survival. This is in agreement with other reports suggesting that growth pattern has no impact on outcome. 25, 29 However, our number of patients is too low to formerly refute the conclusions from other authors regarding the poor outcome associated with presence of blastoid cells at diagnosis 22, 25, 28, 30, 31, 34, 36 or the indolent course of patients having a mantle zone pattern. 27 In contrast with other authors' finding, 25 histologic transformation during the course of the disease was not associated with a shorter survival, but our number of patients is low and the definition of the transformation is not yet standardized.
Because this lymphoma type is rare and only recently individualized, very few prospective studies evaluated the efficacy of a particular treatment modality. In some retrospective studies, an anthracycline-containing chemotherapy was found to be associated with a prolonged overall survival, 23 especially for the patients with favorable IPI scores (low and intermediate risk disease). 24 This finding was not demonstrated in other series 25, 31 but it seems to be confirmed by the regression logistic analysis in our patients. Preliminary results of an ongoing trial suggest that maintenance therapy with interferon alpha could be associated with a prolonged DFS 37, 38 but this benefit was not observed by Teodorovic et al 23 and we did not find any advantage for a maintenance therapy either with chlorambucil or with interferon alpha, probably because of the small number of patients in our study.
A more aggressive therapy, myeloablative chemotherapy with peripheral stem cells transplant, was recently proposed 18,39,40 but did not result in better long-term outcome except in one report, 40 even with the ex vivo purge of the harvest. 41, 42 Different drugs and regimens are currently under investigation, some of them encouraging, such as the monoclonal anti-CD20 antibody, rituximab, which has been associated with a 33% response rate in recurring patients. 43 Another promising regimen, HCVAD/A-M, (hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone alternating with high-dose aracytine and methotrexate), suggested that this program was more effective than other adriamycin plus alkylating agent combinations.
